PSMA-PET in Canada: More questions than answers.

Heather Morris, Luke T Lavallée
{"title":"PSMA-PET in Canada: More questions than answers.","authors":"Heather Morris, Luke T Lavallée","doi":"10.5489/cuaj.8490","DOIUrl":null,"url":null,"abstract":"The era of PSMA-PET has arrived in Canada, and while patients and physicians are excited about how it may personalize treatment and improve outcomes, in many circumstances, it remains unclear how to apply information from PSMA-PET to patient care and if treatment modification based on PET improves outcomes. Furthermore, current access to PSMA-PET in Canada is limited, inequitable, and costly, forcing physicians to contemplate how to best use this resource. It is well-established that PSMA-PET has superior sensitivity and specificity than conventional imaging for prostate cancer detection.1 While Health Canada approved its first PSMA avid radiopharmaceutical, Gallium-98, in October 2022, routine use of PSMAPET is not established in Canada, and access is mainly through trials, private healthcare, and registries. In this month’s CUAJ, Arifin et al examine the impact of PSMA-PET on prostate cancer management and outcomes.2 The authors examined a cohort of patients with or without access to F-DCFPyL PSMA-PET prior to receiving salvage radiotherapy (RT) following biochemical recurrence (BCR) after radical prostatectomy (RP). The PSMA-PET cohort had a higher median presalvage RT prostate-specific antigen (PSA), a longer time from surgery to RT, and a higher proportion of patients receiving RT to pelvic lymph nodes. Despite the higher PSA levels in the PSMA-PET group, oncological outcomes were similar between the two cohorts. When specifically comparing late-salvage RT PSMA patients to early-salvage non-PSMA patients, the outcomes remained similar. These results insinuate that delays in treatment to access PSMA scans may not impact outcomes, or that information obtained from PSMA scans may allow physicians to tailor treatments to render them more effective. Of note, the authors excluded patients who did not receive RT due to negative PET imaging but acknowledged that future studies could include these patients. Emmet et al found that of the patients with a negative PSMA-PET scan who did not receive salvage RT, 66% had PSA progression, with a mean PSA rise of 1.59 ng/mL over the three-year period.3 Further research that includes patients with treatment de-escalation based on PSMA-PET results is required to determine the safety of this approach. A prospective trial of 635 patients reported PSMA-PET-directed therapy alone resulted in a PSA response in 80% of patients.1 A meta-analysis reported a pooled change in management after PSMA-PET of 56% for patient with BCR.4 Higherlevel evidence will hopefully be available in the coming years from a Canadian randomized control trial (PATRON) that is accruing and will examine if PSMA-PET-guided treatment improves cancer outcomes compared to conventional imaging in patients at high risk of recurrence.5 Other exciting areas of research with PSMA-PET include metastasis-directed therapy6 and directing radioligand therapy.7 While it seems certain PSMA-PET imaging will soon have a more established role for Canadian prostate cancer patients, further studies are required to determine how to best use results to improve patient care and how to make this technology available to Canadian patients in an equitable fashion.","PeriodicalId":9574,"journal":{"name":"Canadian Urological Association journal = Journal de l'Association des urologues du Canada","volume":"17 8","pages":"254"},"PeriodicalIF":0.0000,"publicationDate":"2023-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10426419/pdf/cuaj-8-254.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Canadian Urological Association journal = Journal de l'Association des urologues du Canada","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.5489/cuaj.8490","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

The era of PSMA-PET has arrived in Canada, and while patients and physicians are excited about how it may personalize treatment and improve outcomes, in many circumstances, it remains unclear how to apply information from PSMA-PET to patient care and if treatment modification based on PET improves outcomes. Furthermore, current access to PSMA-PET in Canada is limited, inequitable, and costly, forcing physicians to contemplate how to best use this resource. It is well-established that PSMA-PET has superior sensitivity and specificity than conventional imaging for prostate cancer detection.1 While Health Canada approved its first PSMA avid radiopharmaceutical, Gallium-98, in October 2022, routine use of PSMAPET is not established in Canada, and access is mainly through trials, private healthcare, and registries. In this month’s CUAJ, Arifin et al examine the impact of PSMA-PET on prostate cancer management and outcomes.2 The authors examined a cohort of patients with or without access to F-DCFPyL PSMA-PET prior to receiving salvage radiotherapy (RT) following biochemical recurrence (BCR) after radical prostatectomy (RP). The PSMA-PET cohort had a higher median presalvage RT prostate-specific antigen (PSA), a longer time from surgery to RT, and a higher proportion of patients receiving RT to pelvic lymph nodes. Despite the higher PSA levels in the PSMA-PET group, oncological outcomes were similar between the two cohorts. When specifically comparing late-salvage RT PSMA patients to early-salvage non-PSMA patients, the outcomes remained similar. These results insinuate that delays in treatment to access PSMA scans may not impact outcomes, or that information obtained from PSMA scans may allow physicians to tailor treatments to render them more effective. Of note, the authors excluded patients who did not receive RT due to negative PET imaging but acknowledged that future studies could include these patients. Emmet et al found that of the patients with a negative PSMA-PET scan who did not receive salvage RT, 66% had PSA progression, with a mean PSA rise of 1.59 ng/mL over the three-year period.3 Further research that includes patients with treatment de-escalation based on PSMA-PET results is required to determine the safety of this approach. A prospective trial of 635 patients reported PSMA-PET-directed therapy alone resulted in a PSA response in 80% of patients.1 A meta-analysis reported a pooled change in management after PSMA-PET of 56% for patient with BCR.4 Higherlevel evidence will hopefully be available in the coming years from a Canadian randomized control trial (PATRON) that is accruing and will examine if PSMA-PET-guided treatment improves cancer outcomes compared to conventional imaging in patients at high risk of recurrence.5 Other exciting areas of research with PSMA-PET include metastasis-directed therapy6 and directing radioligand therapy.7 While it seems certain PSMA-PET imaging will soon have a more established role for Canadian prostate cancer patients, further studies are required to determine how to best use results to improve patient care and how to make this technology available to Canadian patients in an equitable fashion.
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
PSMA-PET在加拿大:问题多于答案。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
Treatment modalities for small-sized urolithiases and their impact on health-related quality of life. Pilot study to assess the feasibility of self-administered, low-dose methoxyflurane for cystoscopic procedures. An analysis of benign prostatic hyperplasia surgical treatment reimbursement trends across Canada: Examining provincial changes over the recent decade with comparison to cost of living changes. Restricted access and advanced disease in post-pandemic testicular cancer. Comparison of outcomes in patients with and without neurologic diseases undergoing holmium laser enucleation of the prostate.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1